Optiscan Imaging (ASX:OIL) said it is progressing the development of a digital confocal laser endomicroscopic imaging system for use in robotic surgery in collaboration with the Mayo Clinic, according to a Tuesday Australian bourse filing.
The collaboration leveraged Optiscan's expertise in high-resolution endomicroscopic imaging technology and Mayo Clinic's leadership in robotic surgery and clinical care.
The firms have made advancements as part of their 24-month co-development plan to design an imaging system tailored for robotic-assisted breast cancer surgeries.
Its shares fell 9% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.